On March 15, the FDA published its new paper, “Artificial Intelligence and Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,” which outlines specific focus areas regarding the development and use of AI across the medical product lifecycle.
The paper helps further align and streamline the agency’s work in AI.
Read more about the agency’s AI initiatives on its website.
